Kennedy Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Kennedy Capital Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.58M	Sell	1,209,068 -31,624	-3%	-$202K	0.17%	205
2026 Q1	$7.2M	Buy	1,240,692 +26,723	+2%	+$177K	0.15%	228
2025 Q4	$9.53M	Buy	1,213,969 +2,386	+0.2%	+$18.8K	0.2%	173
2025 Q3	$9.86M	Buy	1,211,583 +395,436	+48%	+$2.63M	0.22%	159
2025 Q2	$3.81M	Buy	816,147 +81,060	+11%	+$371K	0.09%	336
2025 Q1	$4.04M	Buy	735,087 +68,992	+10%	+$279K	0.1%	322
2024 Q4	$2.26M	Buy	666,095 +61,238	+10%	+$197K	0.05%	494
2024 Q3	$1.72M	Buy	+604,857	New	+$1.55M	0.04%	536

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Kennedy Capital Management's XERS Position: Q2 2026 in Review

Kennedy Capital Management reduced its Xeris Biopharma Holdings (XERS) stake by 2.5% in Q2 2026, selling an estimated $202K and leaving 1,209,068 shares worth $9.58M. The position accounts for 0.17% of the portfolio, ranked #205.

Kennedy Capital Management first reported a position in XERS in Q3 2024 and has held it in 8 quarters since. The position peaked at $9.86M in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Kennedy Capital Management held 1,209,068 shares of Xeris Biopharma Holdings worth $9.58M as of Q2 2026.
Kennedy Capital Management sold 31,624 Xeris Biopharma Holdings shares in Q2 2026, an estimated $202K.
Xeris Biopharma Holdings made up 0.17% of Kennedy Capital Management's portfolio in Q2 2026, its #205 holding.
Kennedy Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2024 and has held it in 8 quarters since.
Kennedy Capital Management's Xeris Biopharma Holdings position peaked at $9.86M in Q3 2025.
241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.